Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
26.95
+0.07 (0.26%)
May 20, 2026, 4:00 PM EDT - Market closed
Neurogene Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
425.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Autolus Therapeutics | 92.62M |
| 4D Molecular Therapeutics | 88.24M |
| Fulcrum Therapeutics | 80.00M |
| ADC Therapeutics | 79.18M |
| Assembly Biosciences | 71.10M |
| Ovid Therapeutics | 7.12M |
| PureTech Health | 4.66M |
| Artiva Biotherapeutics | 251.00K |
NGNE News
- 8 days ago - Neurogene reports Q1 EPS ($1.39), consensus ($1.27) - TheFly
- 8 days ago - Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates - Business Wire
- 9 days ago - Neurogene Quarterly report: Q1 2026 - Filings
- 9 days ago - Neurogene Earnings release: Q1 2026 - Filings
- 9 days ago - Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy - Business Wire
- 10 days ago - Neurogene Slides: Corporate presentation - Filings
- 14 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 23 days ago - Neurogene to present on ICV delivery in CNS-targeted gene therapy - TheFly